Studieoverzicht
BOOG nr.: |
Status: ( View all )
|
Indication: ( Neoadjuvant )
|
Subindication: |
Menopausal status: |
2018-01 TRAIN-3 | Open | Neoadjuvant | HER2+, any HR | Not applicable | ||||||||||||||
2017-01 NEOLBC | Open | Neoadjuvant | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-04 DIRECT | Follow up | Neoadjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2012-03 TRAIN-2 | Follow up | Neoadjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2010-01 NEO-ZOTAC | Follow up | Neoadjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2007-02 INTENS | Closed | Neoadjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2006-04a TEAM IIa | Closed | Neoadjuvant | Any HER2, HR+ | Postmenopausal |